<DOC>
	<DOCNO>NCT01378416</DOCNO>
	<brief_summary>The purpose study determine pharmacokinetics ( PK ) decitabine administer patient myelodysplastic syndrome ( MDS ) acute myeloid leukemia ( AML ) .</brief_summary>
	<brief_title>Pharmacokinetic Trial Decitabine ( Dacogen ) Administered 3-hour Infusion Patients With Acute Myelogenous Leukemia Myelodysplastic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Each patient meet follow criterion eligible study : 1 . Patients MDS ( de novo secondary ) must 60 year old disease fit recognize FrenchAmericanBritish classification OR chronic myelomonocytic leukemia ( white blood cell [ WBC ] &lt; 12,000/μL ) AND International Prognostic Scoring System score ≥1.5 determine complete blood count , bone marrow assessment bone marrow cytogenetics within 30 day study entry . 2 . Patients AML ( ≥30 % bone marrow blast ) must age 18 year old previously receive standard induction chemotherapy and/or fail approved therapy . 3 . Must Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 . 4 . Must sign Institutional Review Board ( IRB ) approve informed consent form , indicate his/her awareness investigational nature study potential hazard prior initiation studyspecific procedure treatment . 5 . Must adequate renal hepatic function ( creatinine ≤2.0 mg/dL , total bilirubin &lt; 2.0 mg/dL , aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 3.0 X institutional upper limit normal ) . 6 . Must life expectancy least 12 week . 7 . Must recover toxic effect prior therapy entry study . 1 . Patients MDS must candidate highdose chemotherapy , bone marrow stem cell transplant . 2 . Must acute promyelocytic leukemia ( M3 classification ) . 3 . Must receive immunosuppressive therapy 30 day prior study entry . 4 . Must central nervous system ( CNS ) leukemia . 5 . Must receive systemic corticosteroid , interferon , interleukins hormonal therapy within 30 day prior study entry . Use corticosteroid ( topical inhale corticosteroid ) permit prophylactic steroid may use treat prevent transfusion reaction .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Acute myelogenous leukemia</keyword>
	<keyword>myelodysplastic Syndrome</keyword>
	<keyword>cancer</keyword>
</DOC>